Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05999812 |
TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-08-21 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
all trans Retinoic Acid, Atezolizumab, Bevacizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT06006923 |
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-08-23 |
Location
California, United States
Florida, United States Illinois, United States Pennsylvania, United States Washington, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06014502 |
TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-28 |
Location
Louisiana, United States
Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
IMGS-001 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06176885 |
TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-12-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT06106308 |
TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, FOLFIRI, FOLFOX, Onvansertib |
Tags
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan Korea, Republic of Spain Taiwan |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
Tags
MSS/ MMRp
|
| NCT ID NCT05286814 |
TitleM9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | Phase
Phase 2
|
Date Added 2022-03-18 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2019-08-01 |
Location
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05865535 |
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia | Phase
Phase 1
|
Date Added 2023-05-19 |
Location
California, United States
Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
